References
- 1. Buggins AG & Pepper CJ. (2010) The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res. 34(7):837-42 DOI:10.1016/j.leukres.2010.03.011
- 2. Veis DJ, Sorenson CM, Shutter JR & Korsmeyer SJ.(1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell. 75:229-240. DOI: 10.1016/0092-8674(93)80065-M
- 3. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K & Korsmeyer SJ. (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 307:1101-1104. DOI: 10.1126/science. 1106114
- 4. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC & Korsmeyer SJ. (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 426:671-676. DOI: 10.1038/nature02067
- 5. Cimmino, A., Calin, G.A., Fabbri, M. et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 102: 13944–13949. DOI: 10.1073/pnas.0506654102
- 6. Burger JA, Ghia P, Rosenwald A & Caligaris-Cappio F.(2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 114:3367–75. DOI: 10.1182/blood-2009-06-225326
- 7. Maffei R, Martinelli S, Castelli I, Santachiara R, Zucchini P, et al (2010) Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. Leuk Res 34: 312–321. DOI: 10.1016/j.leukres.2009.06.023
- 8. Farahani M, Treweeke AT, Toh CH, Till KJ, Harris RJ, et al (2005) Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 19:524–530. DOI: 10.1038/sj.leu.2403631
- 9. Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M & Kreuzer KA (2011) Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med 17: 619–627. DOI: 10.2119/molmed.2010.00210
- 10. Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, Gliksman M, Goy A & Suh KS. (2016) Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 12;7(28):44735-44762. DOI: 10.18632/oncotarget.8203.
- 11. Ribatti D, Vacca A, Rusnati M & Presta M. (2007) The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine & Growth Factor Reviews 18: 327–334. DOI: DOI: 10.1016/j.cytogfr.2007.04.011
- 12. Jovanović DD (2015). Prognostic markers and apoptosis of malignant lymphocytes derived from peripheral blood and bone marrow. Unpublished doctoral dissertation, University in Kragujevacv, Kragujevac, Serbia (in Serbian)
- 13. Sieklucka M, Bojarska-Junak A, Surdacka A, Hus I, Wasik-Szczepanek E, Dmoszynska A, Wach M, Lewandowska M & Rolinski JM. (2008) Increased Apoptosis of Peripheral Blood and Bone Marrow B and T Cells Correlates with Advanced Stages and Poor Risk Factors in Patients with B-CLL. Blood (ASH Annual Meeting Abstracts). 112: 4162
- 14. Witkowska M, Nowak W, Cebula-Obrzut B, Majchrzak A, Medra A, Robak T & Smolewski P. (2014) Spontaneus in vitro apopotosis of de novo chronic lymphocytic leukemia cells correlates with risk of the disease progression. Cytometry B Clin Cytom, 86(6):410-7. DOI: 10.1002/cyto.b.21163
- 15. Huang J, Fairbrother W & Reed JC. (2015) Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies. Expert Rev Hematol. 8(3):283–297. DOI: 10.1586/17474086.2015.1026321
- 16. Longo P.G., Laurenti L., Gobessi S., Sica S., Leone G. & Efremov DG. (2008) The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 111:846–855. DOI: 10.1182/blood-2007-05-089037
- 17. Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG & Gandhi V. (2014) Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia 2014;16:1036–46. DOI: 10.1016/j.neo.2014.10.002.
- 18. Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW et al. (2002) B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16: 911–919. DOI:10.1038/sj.leu.2402467
- 19. Chen, H., Treweeke, A.T., West, D.C., Till, K.J., Cawley, J.C., Zuzel, M. et al (2000) In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukaemia cells. Blood. 96:3181–3187
- 20. Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M & Kreuzer KA. (2011) Bone marrow stromal cellderived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cellderived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med. 17(7–8):619–627.DOI: 10.2119/molmed.2010.00210
- 21. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF & Kay NE. (2005) VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia. 19, 513–523. DOI: DOI: 10.1038/sj.leu.2403667
- 22. Lee YK, Bone ND, Strege AK, Jelinek DF & Kay NE. (2004) VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG) in B-cell chronic lymphocytic leukemia. Blood 104: 788–794. DOI:10.1182/blood-2003-08-2763
- 23. Maffei, R., Fiorcari, S., Vaisitti, T., Martinelli, S., Benatti, S., Debbia, G., Rossi, D., Zucchini, P., Potenza, L., Luppi, M., Gaidano, G., Deaglio, S. & Marasca, R. (2017) Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia. Oncotarget, 27, 90013–90027. DOI: 10.18632/oncotarget.21341
- 24. Veronese L, Tournilhac O, Verrelle P, Davi F, Dighiero G, Chautard E et al. (2009) Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia. Leukemia Research. 33(12):1623-6. DOI: 10.1016/j.leukres.2009.05.003.
- 25. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brien S, Keating M, Freireich E & Albitar M.(2000) Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 96:2240-2245.
- 26. Karsan A, Yee E, Poirier GG, Zhou P, Craig R & Harlant JM. (1997) Fibroblast Growth Factor-2 Inhibits Endothelial Cell Apoptosis by Bcl-2-Dependent and Independent Mechanisms. American Journal of Pathology. 151(6):1775-84.
- 27. Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM et al. (2016) Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget 7(28):44735-62. DOI: 10.18632/oncotarget.8203
- 28. Krejci P, Dvorakova D, Krahulcova E, Pachernik J, Mayer J, Hampl A & Dvorak P. (2001) FGF-2 abnormalities in B cell chronic lymphocytic and chronic myeloid leukemias. Leukemia. 15:228-237.
- 29. Kini AR, Kay NE & Peterson LC. (2000) Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 14:1414-1418. DOI: 10.1038/sj.leu.2401825
- 30. König A, Menzel T, Lynen S, Wrazel L, Rosén A, Al-Katib A, Raveche E & Gabrilove JL. (1997) Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia. 11(2):258–26